WuXi XDC Cayman Inc. is a contract research, development and manufacturing organization (CRDMO) focused on antibody-drug conjugates (ADCs) and other bioconjugates. It provides integrated, end-to-end services that encompass discovery, development and cGMP manufacturing of key intermediates such as chemical payload-linkers and biologics, as well as bioconjugate drug substances and drug products.
Formed as a joint venture between WuXi Biologics and WuXi STA, the company maintains its headquarters in Wuxi, China, with additional operations in Shanghai and Changzhou. It has pursued international expansion, including facilities in Singapore. WuXi XDC Cayman Inc. is listed on the Hong Kong Stock Exchange.
Official website: wuxixdc.com
To provide comprehensive coverage, we aggregate data and news under the name WuXi XDC, encompassing the following company names, divisions, and related entities:
藥明合聯生物技術有限公司.
This list encompasses current and former names, alternate names, and key divisions associated with WuXi XDC, ensuring you can easily find all relevant information under a single, unified profile.
